Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte’s raise:
🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after …
→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte’s raise:
🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after …